However, unlike combinations of TKIs, PARP inhibitor combinations may prove more tolerable for patients since toxicities are less likely to overlap and synergy will be most pronounced in SCLC cells with impaired DDR, allowing for dose decreases to minimize side effects. This evidence concerns the gene PARP1 and small cell lung carcinoma.